PDL BioPharma, Inc.
(NASDAQ : PDLI)

( )
PDLI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.31%86.001.3%$1325.78m
AMGNAmgen Inc.
-0.93%201.981.2%$608.04m
GILDGilead Sciences, Inc.
-0.91%68.550.9%$534.22m
LOXOLoxo Oncology Inc
0.12%233.7812.7%$511.41m
BIIBBiogen Inc.
0.46%338.961.3%$413.85m
VRTXVertex Pharmaceuticals Incorporated
-0.42%193.881.9%$324.40m
ILMNIllumina, Inc.
-2.92%303.623.5%$304.88m
REGNRegeneron Pharmaceuticals, Inc.
-3.36%404.752.6%$294.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.36%114.292.0%$213.93m
INCYIncyte Corporation
-1.39%77.332.5%$145.56m
AAgilent Technologies, Inc.
-0.89%71.291.5%$145.13m
EXASExact Sciences Corporation
-3.46%76.0725.3%$135.78m
SRPTSarepta Therapeutics, Inc.
-2.05%120.2815.4%$130.09m
LGNDLigand Pharmaceuticals Incorporated
-4.23%112.9123.1%$119.15m
NBIXNeurocrine Biosciences, Inc.
-0.27%91.285.1%$97.05m

Company Profile

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.